43 completed, 5 not yet recruiting, 4 recruiting, 4 unknown. 21 Phase 1, 19 Phase 2, 16 Phase 3, 7 Not applicable, 2 Phase 4.
Follow Placebo solution: new trials by email Literature Review of Placebo solution trials Research Report on Placebo solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis Para-Tyrosine supplementation, Placebo solution - Sepsis | Phase 2 | Suspended | University of Pecs | 296 | 2027-01-01 | 2025-03-30 |
| A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS. Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120, Placebo solution - Obesity / Overweight, Obesity (BMI Equal to or >30) | Phase 2 | Not yet recruiting | EktaH | 31 | 2026-10-20 | 2026-10-20 |
| Impact of Preoperative Oral Carbohydrate Loading on Insulin Resistance in Pediatric Cardiac Surgery Patients Carbohydrate, placebo solution - Cardiac Surgery, Insulin Resistance | Not applicable | Not yet recruiting | Rifdhani Fakhrudin Nur | 44 | 2026-08-25 | 2026-07-27 |
| Effects of Creatine and Carbohydrate Supplementation on Endurance Performance Creatine Monohydrate, Carbohydrate, Creatine Monohydrate and Carbohydrate - Exercise Performance Recovery | Not applicable | Not yet recruiting | California Polytechnic State University-San Luis Obispo | 12 | 2026-07-15 | 2026-07-21 |
| Effect of Insulin Lowering on Lipogenesis Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70% - Hyperinsulinemia, Insulin Resistance | Phase 1 | Recruiting | Columbia University | 25 | 2026-07-01 | 2026-07-06 |
| Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy Scalp Stimulating Serum, Red Light Hair Growth Cap, Placebo scalp-stimulating serum - Androgenic Alopecia, Female Pattern Hair Loss | Not applicable | Recruiting | K. Kay Durairaj, MD, FACS, A Medical Corporation | 40 | 2026-03-17 | 2026-09-09 |
| Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery Maltodextrin solution, Placebo solution - Left Ventricular Dysfunction, Quality of Recovery | Phase 4 | Not yet recruiting | Jewish General Hospital | 70 | 2025-12-01 | 2025-02-24 |
| Pilot and Feasibility Study of Impact of SDF 38% Application on Oral Health of Elderly With Autonomy Loss Silver diamine Fluoride 38%, placebo solution - Dental Caries, Elderly | Phase 4 | Not yet recruiting | Université de Montréal | 60 | 2025-10-01 | 2025-09-26 |
| Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults L608 Liposomal inhalation suspension, Placebo Solution - Healthy Adult Participants | Phase 1 | Recruiting | Pharmosa Biopharm Inc. | 40 | 2025-04-11 | 2026-07-22 |
| Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults L608 Inhalation Solution, Placebo solution - Pulmonary Arterial Hypertension | Phase 1 | Completed | Pharmosa Biopharm Inc. | 64 | 2023-08-30 | 2024-10-16 |
| Glycemic Effect of Diazoxide in NAFLD Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo - Hyperinsulinemia, Insulin Resistance | Phase 1 | Completed | Columbia University | 22 | 2023-08-01 | 2026-09-30 |
| Ketone Monoester and Blood Pressure BHB supplement, Placebo solution - Blood Pressure | Not applicable | Unknown | Université de Sherbrooke | 15 | 2023-06-01 | 2023-04-10 |
| Topical Absorption of Glutathione-cyclodextrin Complex in Healthy Human Subjects Improves Immune Response Against Mycobacterium Infection Glutaryl Solution, Placebo Solution - Glutathione-cyclodextrin Complex Absorption | Phase 1 | Completed | Western University of Health Sciences | 30 | 2022-07-11 | 2023-07-03 |
| Naldebain for Pain Management of Laparoscopic Cholecystectomy Dinalbuphine sebacate, Placebo solution - Pain, Postoperative, Pain, Chronic | Phase 2 / Phase 3 | Completed | E-DA Hospital | 80 | 2021-08-30 | 2022-04-20 |
| Naldebain for Pain Control After Bariatric Surgery Dinalbuphine sebacate, Placebo solution - Pain, Postoperative, Pain, Chronic | Phase 2 / Phase 3 | Unknown | E-DA Hospital | 60 | 2021-06-24 | 2021-12-28 |
| Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke Alogenic adipose tissue-derived stem cells, Placebo solution - Ischemic Stroke, Adipose Tissue-derived Stem Cell | Phase 2 | Unknown | Instituto de Investigación Hospital Universitario La Paz | 30 | 2021-01-20 | 2023-05-30 |
| Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis K-321 Solution, Placebo Solution - Fuchs' Endothelial Corneal Dystrophy | Phase 2 | Completed | Kowa Research Institute, Inc. | 65 | 2020-06-23 | 2024-11-05 |
| Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 Methylprednisolone Sodium Succinate, Placebo solution - SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia | Phase 2 | Completed | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | 416 | 2020-04-18 | 2021-07-28 |
| A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink. BI 474121 tablet, Placebo tablet, BI 474121 oral solution - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 66 | 2020-01-09 | 2024-03-26 |
| Propolis for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer 15% Propolis solution, Placebo Solution, Standard oral care - Oral Mucositis in Head and Neck Cancer | Not applicable | Completed | Ankara Oncology Research and Training Hospital | 140 | 2019-05-27 | 2026-05-19 |
Showing 20 of 63. Sign in to see all of them.
Insulin Resistance (4) · Keratoconus (3) · Mucositis (3) · Obesity (3) · Pulmonary Arterial Hypertension (3) · Alopecia (2) · Chronic Pain (2) · Hyperinsulinism (2) · Hypertension, Pulmonary (2) · Hypogonadism (2) · Low Back Pain (2) · Non-alcoholic Fatty Liver Disease (2) · Pain, Postoperative (2) · Prediabetic State (2) · Pulmonary Disease, Chronic Obstructive (2)
Boehringer Ingelheim (7) · Eli Lilly and Company (3) · Glaukos Corporation (3) · GlaxoSmithKline (3) · Pharmosa Biopharm Inc. (3) · ASIT Biotech S.A. (2) · BioTech Tools S.A. (2) · Columbia University (2) · E-DA Hospital (2) · INSYS Therapeutics Inc (2) · POLYSAN Scientific & Technological Pharmaceutical Company (2) · TME Pharma AG (2) · Universidade Federal do Rio Grande do Norte (2) · Ankara Oncology Research and Training Hospital (1) · California Polytechnic State University-San Luis Obispo (1)
United States (21) · Germany (8) · Canada (7) · Spain (5) · United Kingdom (5) · Belgium (3) · Puerto Rico (3) · Russia (3) · Taiwan (3) · Argentina (2) · Australia (2) · Israel (2) · Italy (2) · Mexico (2) · Romania (2)
Bruno CV Gurgel, Doctor (2) · Joshua R Cook, MD, PhD (2) · Kai Riecke, MD (2) · Neha Parikh (2) · Vineeta Belanger (2) · Alexandra B Kimball, MD (1) · Andre M Beer, MD, PhD (1) · Anja Braschoss, MD (1) · Anthony Andrasfay (1) · Bachert Claus, Prof Dr (1) · Benji Crane (1) · Cesar Ochoa, MD (1)
PMID 38224135, PMID 15514282, PMID 22087222, PMID 23294774, PMID 24762094, PMID 25163699, PMID 25912221, PMID 26158605, PMID 26176325, PMID 26498057, PMID 26691396, PMID 27161178, PMID 28755389, PMID 28800383, PMID 29226626, PMID 30428930, PMID 30637626, PMID 30844425, PMID 30957581, PMID 31529295, PMID 32391156, PMID 32785710, PMID 34917633, PMID 36894938, PMID 38811045
2016 (1), 2017 (1), 2019 (1), K12DK133995 (1), K23DK140614 (1)